Company intelligence / Profile preview

ProPedix

Ownership: Private
Development stage: Preclinical

Overview

ProPedix is developing an innovative topical treatment for Athlete’s Foot and other fungal conditions, with a product launch expected in early 2025. The company focuses on science-backed solutions targeting dermatological health at the intersection of biopharma and consumer health. No clinical trial results are publicly available yet.[1]

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Topical compositions (pharmaceutical creams/ointments)
Industry: Biotech

Drug pipeline

1 asset

Dryello

Unknown

Beyond the preview

Go deeper on ProPedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProPedix.

Explore the full profile